Day: November 25, 2022

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Nov. 25, 2022 (GLOBE NEWSWIRE) — P2 Gold Inc. (“P2” or the “Company”) (TSX-V:PGLD) (OTCQB:PGLDF) reports that it has revised the terms of its previously announced (see news release of October 25, 2022) non-brokered private placement of up to 4.0 million units (the “Units”) at a price of $0.27 per unit for gross proceeds of up to approximately $1 million (the “Offering”). Each Unit will now consist of one common share in the capital of the Company (a “Share”) and one whole (previously one-half) common share purchase warrant (a “Warrant”). Each Warrant will now entitle the holder to purchase one additional common share in the capital of the Company at an exercise price of $0.40 per common share (previously...

BOCA RATON, Fla., Nov. 25, 2022 (GLOBE NEWSWIRE) — First Wave BioPharma, Inc. (NASDAQ: FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-system therapies for gastrointestinal diseases, today announced that its Board of Directors declared a dividend of 0.001 of a share of newly-designated Series F Preferred Stock, par value $0.0001 per share, for each outstanding share of the Company’s common stock held of record as of 5:00 p.m. Eastern Time on December 5, 2022. The outstanding shares of Series F Preferred Stock will vote together with the outstanding shares of the Company’s common stock, as a single class, exclusively with respect to a reverse stock split, as well as any proposal to adjourn any meeting of stockholders called for the purpose...

CALGARY, Alberta, Nov. 25, 2022 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, has received notification from the Nasdaq Stock Market LLC Listing Qualifications Department that it was not in compliance with the minimum bid price requirement set forth in Nasdaq Rule 5550(a)(2) since the closing bid price for the Company’s common shares listed on Nasdaq was below US$1.00 for 30 consecutive business days. Nasdaq Rule 5550(a)(2) requires the shares to maintain a minimum bid price of US$1.00 per share, and Nasdaq Rule 5810(c)(3)(A) provides that failure to meet such a requirement exists when the bid price of the shares is below...

TORONTO, Nov. 25, 2022 (GLOBE NEWSWIRE) — Jade Power Trust (“Jade Power” or the “Trust”) (TSXV: JPWR.UN) announces the resignation of Amar Bhalla from the Board of Directors (the “Board”) of Jade Power Administrator Inc., administrator of the Trust. “On behalf of the Trust, I would like to thank Amar for his seven years of valuable contributions to the Board. We wish him all the best in his future endeavours,” said Mr. Ravi Sood, Chairman of the Trust. In connection with his resignation from the Board, Mr. Bhalla said “Congratulations to Jade Power and management for a successful sale of all of the Trust’s assets. It has been a pleasure serving on the Board for the past seven years and witnessing the development of the Jade Power business start to finish.” The Board is considering the Trust’s options with respect to the future...

This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated September 7, 2022 to its short form base shelf prospectus dated June 16, 2021 TORONTO, Nov. 25, 2022 (GLOBE NEWSWIRE) — Northland Power Inc. (“Northland” or the “Company”) (TSX: NPI) announced today that it intends to redeem all of its 4,800,000 issued and outstanding Cumulative Rate Reset Preferred Shares, Series 3 (the “Series 3 Preferred Shares”) on January 3, 2023 (the “Redemption Date”) at a price of $25.00 per Series 3 Preferred Share together with all accrued and unpaid dividends thereon up to, but excluding, December 31, 2022 (less any tax required to be deducted or withheld by the Company) (the “Redemption Price”) for an aggregate total of $121.5 million. The final quarterly dividend of $0.3175 per Series...

MONTREAL, Nov. 25, 2022 (GLOBE NEWSWIRE) — PyroGenesis Canada Inc. (http://pyrogenesis.com) (TSX: PYR) (NASDAQ: PYR) (FRA: 8PY), a TSX30® and a Deloitte Technology Fast 50TM high-tech company (hereinafter referred to as the “Company” or “PyroGenesis”), that designs, develops, manufactures and commercializes advanced plasma processes and sustainable solutions which are geared to reduce greenhouse gases (GHG), announced today that on November 22, 2022, it received a written notification (the “Notification Letter”) from the Nasdaq Stock Market LLC (“NASDAQ”) indicating that, for the last thirty consecutive business days, the closing bid price for the Company’s common shares (the “Shares”) had closed below the minimum bid price of US$1.00 per share listing requirement under NASDAQ Listing Rule 5550(a)(2). The NASDAQ notification letter...

VANCOUVER, British Columbia, Nov. 25, 2022 (GLOBE NEWSWIRE) — VERSES Technologies Inc. (NEO:VERS) (“VERSES” or the “Company”), a cognitive computing platform provider specializing in the next generation of artificial intelligence solutions, announces its plan to amend certain terms of an aggregate of 18,100,714 Class A subordinate voting share purchase warrants (“Class A Warrants”) consisting of: (i) 6,591,631 Class A warrants issued on February 22, 2022 (the “February Warrants”); (ii) 3,909,906 Class A Warrants issued on March 3, 2022 (the “March Warrants” and together with the February Warrants, the “Old Warrants”); and (iii) an aggregate of 7,599,177 Class A Warrants issued on August 10, August 17 and August 26, 2022 (the “August Warrants”) as further described in the Company’s news release dated August 29,...

$5 million PIPE supports near-term capital needs to meet equipment milestones CHASKA, Minn., Nov. 25, 2022 (GLOBE NEWSWIRE) — Lifecore Biomedical, Inc. (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced the closing of a $5 million private placement (“PIPE”) of its common stock with affiliates of Wynnefield Capital, Inc. (“Wynnefield Capital”), a longtime stockholder of the Company, at $7.97 per share. The Company expects to use the proceeds for near-term capital expenditures associated with equipment manufacturing milestones in its effort to ramp up capacity in response to demand from its development pipeline and project portfolio. “Lifecore continues to see increased demand for its specialized capacity to manufacture complex sterile injectable pharmaceutical...